CLL update from ICML17: Current treatment and future directions for patients
The explosion of immuno-oncology
Why should elderly AML patients take part in clinical trials?
Overcoming the shortfalls of ibrutinib with fludarabine in CLL patientss
What does the CLL forum data tell us?